A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Low Breast Carcinoma
Interventions: DRUG: SHR-A1811 for injection
Sponsor: Henan Cancer Hospital